A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Clinical trial NCT03255070 · COMPLETED
Trial details
- NCT number
- NCT03255070
- Sponsor
- Ambrx, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-20
- Primary completion
- 2023-09-13
- Enrollment
- 106
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.